ArticleSeminars in liver disease2022
Management of Acute Liver Failure: Update 2022.
Article in Seminars in liver disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- Liver support systems for adults with acute liver failure.The Cochrane database of systematic reviews · 2026Pooled it
- Efficacy of Schisandra chinensis in liver injury: a systematic review and preclinical meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation.Hepatology international · 2024Guideline
- Pre-Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial.Alimentary pharmacology & therapeutics · 2026Trial
- Liver Transplantation Despite Active Intracranial Hemorrhage in Acetaminophen-Induced Acute Liver Failure: A Case Report.Clinical case reports · 2026Article
- The DILI-Inpt Prognostic Score to Identify Hospitalized Idiosyncratic DILI Patients at Risk for Adverse Outcomes.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Observational
- Herpes Simplex Virus Hepatitis: An Overlooked Cause of Acute Liver Failure Across a Broad Spectrum of Immunocompromise.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Comparative pathophysiological modeling: the advantage of "two-hit" over "one-hit" in acute liver failure studies.In vitro cellular & developmental biology. Animal · 2026Article
- Delayed Ischemic Hepatocellular Injury Following Cemented Total Hip Arthroplasty: A Case Report Within the Spectrum of Bone Cement Implantation Syndrome.Life (Basel, Switzerland) · 2026Article
- Protein Lactylation in Liver Disease: A Comprehensive Review.Expert reviews in molecular medicine · 2026Review
- miR-19b-3p engineered adipose-derived stem cell exosomes attenuate acute liver failure via promoting tissue repair and microenvironment remodeling.Materials today. Bio · 2026Article
- Development and validation of a risk prediction model for hepatorenal syndrome in hepatic failure patients based on glucose-6-phosphate dehydrogenase and hepatic and renal function biochemical parameters.Journal of medical biochemistry · 2026Article
- Identification of Key Genes in Acute Liver Failure via Analysis of Programmed Cell Death Patterns.International journal of genomics · 2026Article
- Low-Volume Plasma Exchange Combined With a Double Plasma Molecular Adsorption System is Superior to Standard-Volume Plasma Exchange in improving the MELD Score and Reducing Plasma Consumption in Adult Patients With Acute Liver Failure: A Multicenter Retrospective Cohort Study From Heilongjiang Province.Canadian journal of gastroenterology & hepatology · 2026Article
- Dihydroquercetin alleviates mitochondrial dysfunction and inhibits NLRP3-mediated pyroptosis in primary hepatocytes from chronic liver failure patients.American journal of translational research · 2026Article
- The protective efficacy of baricitinib against lipopolysaccharide / D-Galactosamine-Induced acute liver Injury.Frontiers in pharmacology · 2026Article
- Early peripheral monocyte dynamics are associated with 28-day mortality in acute liver failure: an exploratory longitudinal cohort study.Frontiers in medicine · 2026Article
- Management of acute liver failure-an updated literature review.World journal of critical care medicine · 2025Review
- RAC1 as a novel therapeutic target for acute liver failure.JHEP reports : innovation in hepatology · 2025Article
- Body mass index and its association with clinical outcomes in acute liver failure.World journal of clinical cases · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Abbreviated pathogenesis and clinical course of the acute liver failure syndrome. The pathogenesis and clinical course of the syndrome of acute liver failure (ALF) differs depending upon the etiology of the primary liver injury. In turn, the severity of the liver injury and resulting synthetic failure is often the primary determinant of whether a patient is referred for emergency liver transplantation. Injuries by viral etiologies trigger the innate immune system via pathogen-associated molecular patterns (PAMPs), while toxin-induced (and presumably ischemia-induced) injuries do so via damage-associated molecular patterns (DAMPs). The course of the clinical syndrome further depends upon the relative intensity and composition of cytokine release, resulting in an early proinflammatory phenotype (SIRS) and later compensatory anti-inflammatory response phenotype (CARS). The outcomes of overwhelming immune activation are the systemic (extrahepatic) features of ALF (cardiovascular collapse, cerebral edema, acute kidney injury, respiratory failure, sepsis) which ultimately determine the likelihood of death.Acute liver failure (ALF) continues to carry a high risk of mortality or the need for transplantation despite recent improvements in overall outcomes over the past two decades. Optimal management begins with identifying that liver failure is indeed present and its etiology, since outcomes and the need for transplantation vary widely across the different etiologies. Most causes of ALF can be divided into hyperacute (ischemia and acetaminophen) and subacute types (other etiologies), based on time of evolution of signs and symptoms of liver failure; the former evolve in 3 to 4 days and the latter typically in 2 to 4 weeks. Both involve intense release of cytokines and hepatocellular contents into the circulation with multiorgan effects/consequences.Management involves optimizing fluid balance and cardiovascular support, including the use of continuous renal replacement therapy, vasopressors, and pulmonary ventilation. Early evaluation for liver transplantation is advised particularly for acetaminophen toxicity, which evolves so rapidly that delay is likely to lead to death.Vasopressor support, high-grade hepatic encephalopathy, and unfavorable (subacute) etiologies heighten the need for urgent listing for liver transplantation. Prognostic scores such as Kings Criteria, Model for End-Stage Liver Disease, and the Acute Liver Failure Group prognostic index take these features into account and provide reasonable but imperfect predictive accuracy. Future treatments may include liver support devices and/or agents that improve hepatocyte regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.